MYLK

Across TCGA pan-cancer cohorts, MYLK mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MYLK’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where MYLK mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MYLK is over-expressed in tumor, although a few such as COAD and HNSC show the opposite, repressed pattern.

COAD, HNSC, and CCRCC are the cancer types where MYLK tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYLK mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	−2.471	<.001	11	view →
HNSC	Male	All	−0.960	<.001	11	view →
CCRCC	Male	III,IV	−0.717	<.001	11	view →
LSCC	Male	II,III,IV	−1.468	<.001	9	view →
LUAD	Male	III,IV	−1.216	<.001	9	view →
PDAC	Female	All	+0.653	<.001	6	view →
OV	All	All	−1.411	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MYLK–COAD

Open the COAD breakdown →